Routine DNA tests will put NHS at the 'forefront of medicine'From 1 October, hospitals across England will be connected to specialist centres that read, analyse and interpret patient DNA to help diagnose rare diseases, match patients to the most effective treatments, and reduce adverse drug reactions.
The move marks a big step towards “precision medicine”, which offers more efficient therapies that are tailored to individual patients.
Under the service, new cancer patients will routinely have their tumour DNA screened for key mutations that can point doctors towards the best drug to use in treatment, or to clinical trials of experimental therapies that patients are likely to benefit from.https://www.theguardian.com/science/201 ... -screening
It looks like they will screen for some mutations for most cancers and the whole genome for other cancers. Canada is doing a clinical trial on this. US insurance companies don't routinely cover this - but I suspect that they do if the doctor indicates that it is needed given that a number of people here have had it done. I think that it should be routinely done to determine if there's an aggressive mutation or if some drugs are contraindicated by the genomic information.
6/17: ER rectal bleeding; Colonoscopy
7/17: Stage 3B rectal. T3N1bM0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/17-9/17: Xeloda +radiation
7/5: CEA 2.7; 8/16: 1.9; 9/8: 1.8; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8
MSS, KRAS G12D
10/17: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/17: LAR, Temp Ileostomy, Path Complete Response
CapeOx 8 cycles 12/17-6/18